Treatment with Incomplete Freund's Adjuvant and Delays Diabetes Via an Interleukin-17-secretion-independent Pathway

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2015 Jul 3

PMID 26136917

Authors

Hai-Ping Wang

Zhi-Gao He

Affiliations

Soon will be listed here.

Abstract

Non-obese diabetes (NOD) mice are widely used as an animal model in studies of type I diabetes (TID). Treatment with complete Freund's adjuvant (CFA) in pro-diabetic NOD mice is known to inhibit disease progression by activating CD1d-specific natural killer (NK) T cells and inducing interleukin (IL)-17 secretion in innate immune cells. The aim of the present study was to examine the effect of incomplete Freund's adjuvant (IFA) and treatment on the development of TID in NOD mice. This combined treatment of IFA and , a microbe that infects the liver and is primarily combatted by NK and cytotoxic T lymphocytes, was applied to mimic CFA treatment in pro-diabetic NOD mice. The combined IFA + treatment effectively delayed TID development in the NOD mice. In contrast to CFA, the IFA + treatment did not induce T cells or innate immune cells to secrete IL-17. However, increased levels of regulatory T cells were detected. Furthermore, IFA + mice exhibited higher levels of IgG2a, although no notable T helper 1 cell response was observed when compared with the CFA or IFA control treated mice. Therefore, combined IFA + treatment was shown to delay TID development in NOD mice via a novel mechanism, which was independent from the secretion of IL-17 by CFA-activated NKT cells.

References

Duarte N, Stenstrom M, Campino S, Bergman M, Lundholm M, Holmberg D . Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol. 2004; 173(5):3112-8. DOI: 10.4049/jimmunol.173.5.3112. View

Alam C, Valkonen S, Palagani V, Jalava J, Eerola E, Hanninen A . Inflammatory tendencies and overproduction of IL-17 in the colon of young NOD mice are counteracted with diet change. Diabetes. 2010; 59(9):2237-46. PMC: 2927946. DOI: 10.2337/db10-0147. View

Tigno-Aranjuez J, Lehmann P, Tary-Lehmann M . Dissociated induction of cytotoxicity and DTH by CFA and CpG. J Immunother. 2009; 32(4):389-98. DOI: 10.1097/CJI.0b013e31819d79a7. View

Lockhart E, Green A, Flynn J . IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol. 2006; 177(7):4662-9. DOI: 10.4049/jimmunol.177.7.4662. View

Yeung V, Gieni R, Umetsu D, DeKruyff R . Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol. 1998; 161(8):4146-52. View

Qin H, Chaturvedi P, Singh B . In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol. 2004; 16(12):1723-32. DOI: 10.1093/intimm/dxh173. View

Aoki C, Borchers A, Ridgway W, Keen C, Ansari A, Gershwin M . NOD mice and autoimmunity. Autoimmun Rev. 2005; 4(6):373-9. DOI: 10.1016/j.autrev.2005.02.002. View

Lee I, Qin H, Priatel J, Tan R . Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes. Eur J Immunol. 2007; 38(1):82-9. DOI: 10.1002/eji.200737189. View

Qin H, Singh B . BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J Autoimmun. 1997; 10(3):271-8. DOI: 10.1006/jaut.1997.0136. View

10.

Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y . Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 1980; 29(1):1-13. DOI: 10.1538/expanim1978.29.1_1. View

11.

Lehuen A, Diana J, Zaccone P, Cooke A . Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol. 2010; 10(7):501-13. DOI: 10.1038/nri2787. View

12.

Qin H, Elliott J, Lakey J, Rajotte R, Singh B . Endogenous immune response to glutamic acid decarboxylase (GAD67) in NOD mice is modulated by adjuvant immunotherapy. J Autoimmun. 1999; 11(6):591-601. DOI: 10.1006/jaut.1998.0243. View

13.

Kukreja A, Costi G, Marker J, Zhang C, Sinha S, Sun Z . NKT cell defects in NOD mice suggest therapeutic opportunities. J Autoimmun. 2002; 19(3):117-28. DOI: 10.1006/jaut.2002.0609. View

14.

McInerney M, Pek S, Thomas D . Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes. 1991; 40(6):715-25. DOI: 10.2337/diab.40.6.715. View

15.

Tisch R, Wang B, Serreze D . Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol. 1999; 163(3):1178-87. View

16.

Mori Y, Kodaka T, Kato T, Kanagawa E, Kanagawa O . Critical role of IFN-gamma in CFA-mediated protection of NOD mice from diabetes development. Int Immunol. 2009; 21(11):1291-9. DOI: 10.1093/intimm/dxp097. View

17.

Lee I, Qin H, Trudeau J, Dutz J, Tan R . Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J Immunol. 2004; 172(2):937-42. DOI: 10.4049/jimmunol.172.2.937. View

18.

Emoto M, Yoshida T, Fukuda T, Kawamura I, Mitsuyama M, Kita E . Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation. Infect Immun. 2010; 78(6):2667-76. PMC: 2876567. DOI: 10.1128/IAI.01441-09. View

19.

Lee I, van den Elzen P, Tan R, Priatel J . NKT cells are required for complete Freund's adjuvant-mediated protection from autoimmune diabetes. J Immunol. 2011; 187(6):2898-904. DOI: 10.4049/jimmunol.1002551. View

20.

Godfrey D, Kronenberg M . Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004; 114(10):1379-88. PMC: 525753. DOI: 10.1172/JCI23594. View